비교리스트

 카트 문의
시장보고서
상품코드
1529763

날트렉손 및 부프레노르핀 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 투여 경로별, 용도별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Naltrexone And Buprenorphine Market Size, Share & Trends Analysis Report By Product, By Route of Administration (Oral, Injectable) By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 202 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

날트렉손 및 부프레노르핀 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 나트렉손 및 부프레노르핀 시장 규모는 2030년까지 84억 2,000만 달러에 달할 것으로 예상되며, 2024-2030년 연평균 12.41% 성장할 것으로 예측됩니다. 시장 성장의 주요 요인은 약물 사용 장애 발생률 증가, 위기 상황에 대처하기 위한 정부의 노력 증가, 오피오이드 사용 장애 치료에 대한 인식 증가 등입니다. 이러한 요인들은 예측 기간 동안 업계의 확장을 크게 촉진하고 중독 치료 솔루션의 발전과 접근성 향상을 촉진할 것으로 예상됩니다.

World Drug Report 2023은 약물 사용 장애의 세계 동향에 초점을 맞추고 오피오이드가 과다 복용으로 인한 사망의 주요 원인이며, 장애와 조기 사망으로 인한 손실 연수의 주요 요인임을 강조합니다. 오피오이드 사용 장애(OUD)는 전 세계적으로 수백만 명이 앓고 있으며, COVID-19 팬데믹으로 인해 치료 접근성 격차가 악화되고 있습니다. 주요 남용 약물은 유럽과 아시아에서는 오피오이드, 라틴아메리카에서는 코카인, 동아시아 및 동남아시아에서는 메스암페타민 등 지역별로 차이가 있습니다. 낙인과 차별이 치료 노력을 방해하고 있으며, 도움이 필요한 사람들 중 20% 미만이 치료를 받고 있는 실정입니다. 보고서는 이러한 복잡한 건강 문제와 사회적 문제를 해결하기 위한 국제 협력을 촉구하고 있습니다.

또한, 2024년 2월 SAMHSA의 승인으로 지역 정신건강 서비스 블록 보조금과 약물 사용 예방, 치료 및 회복 서비스 블록 보조금 보조금 4,660만 달러가 정신건강 및 약물 사용 서비스에 배정되었습니다. 정신건강 및 약물 사용 서비스에 배정되었습니다. 또한, 미국 재무부의 자금 6,750만 달러가 위스콘신주의 이러한 노력을 지원하기 위해 배정되었습니다.

또한, 업계 기업들은 유통망 강화, 의료 서비스 제공자와의 전략적 제휴, R&D 투자 확대 등 전략적 이니셔티브를 통해 시장 성장을 촉진하고 있습니다. 예를 들어, 2023년 7월 Titan Pharmaceuticals, Inc.와 Fedson, Inc.는 자산 매매 계약을 체결하여 Titan이 ProNeura의 자산 일부를 매각하기로 했습니다. 이 계약에는 ProNeura 약물전달 기술을 기반으로 구축된 약물 중독 치료제 포트폴리오 및 기타 초기 개발 이니셔티브가 포함됩니다. 약물중독 포트폴리오에는 나르메펜과 프로부핀의 임플란트 프로그램이 포함돼 있습니다. 또한 2023년 9월, Camurus AB는 중등도에서 중증의 OUD 치료를 위한 주 1회 및월 1회 투약이 가능한 브릭사디를 포함한 브릭사디(Brixadi)를 발표했습니다. 이러한 노력은 치료에 대한 접근성과 효능을 확대하여 치료의 진전을 크게 촉진하는 것을 목표로 하고 있습니다.

날트렉손 및 부프레노르핀 시장 보고서 하이라이트

  • 탄탄한 의료 인프라, 높은 약물 사용 장애 유병률, 중독 치료 지원을 위한 정부의 적극적인 노력에 힘입어 북미는 2023년 39.39%로 가장 큰 매출 점유율을 차지했습니다.
  • 제품별로는 부프레노르핀(Buprenorphine) 부문이 2023년 70.02%의 점유율로 시장을 장악하고 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 이 부문의 성장은 제품 출시, 제휴, M&A, 규제 당국의 승인, 효능을 입증하는 임상시험, 치료 시작률을 높이는 기타 요인 등 주요 기업들이 채택한 다양한 전략에 기인하는 것으로 보입니다.
  • 투여 경로별로는 경구 투여 부문이 2023년 55.87%의 점유율을 차지했습니다. 반면, 부프레노르핀 부문에서는 주사제 투여가 2023년 65.04%로 가장 큰 비중을 차지했습니다.
  • 용도별로는 OUD 부문이 2023년 69.03%의 점유율을 차지했습니다. 나트렉손은 OUD 관리에 효과적이라는 것이 널리 알려져 있으며, 이는 치료 프로그램에 광범위하게 채택되고 있습니다.
  • 유통 채널별로는 병원 내 약국이 2023년 48.26%의 점유율을 차지하며 세계 시장을 장악했습니다. 병원 내 약국의 성장은 부프레노르핀과 같은 비경구용 OUD 치료제를 투여하고, 의사의 감독하에 치료를 보장하며, 필수 의약품에 대한 접근을 촉진하는 데 중요한 역할을 하는 데 기인합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 날트렉손 및 부프레노르핀 시장 변수, 동향, 범위

  • 날트렉손 및 부프레노르핀 시장 계통 전망
    • 상부 시장 전망
    • 보조 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 날트렉손 및 부프레노르핀 시장 분석 툴
    • Porter's Five Forces 분석
    • PESTLE 분석
  • 파이프라인 분석
  • 가격 분석
  • 임플란트 치료를 선택할 때 환자와 의료 제공자 고려사항
  • 대상 인구 분석
  • 날트렉손 및 부프레노르핀 피하 흡수성 임플란트 전체 시장(TAM) 분석

제4장 날트렉손 및 부프레노르핀 시장 분석 : 제품별(2018-2030년)

  • 날트렉손 및 부프레노르핀 : 제품 변동 분석
  • 날트렉손 및 부프레노르핀 시장 분석 : 제품 시장별
  • 날트렉손
    • 시장 매출 추정과 예측(2018-2030년)
  • 부프레노르핀
    • 시장 매출 추정과 예측(2018-2030년)
    • BELBUCA
    • Sublocade
    • Suboxone
    • Zubsolv
    • 기타

제5장 날트렉손 및 부프레노르핀 시장 분석 : 투여 경로별(2018-2030년)

  • 날트렉손 및 부프레노르핀 : 투여 경로 변동 분석
  • 날트렉손 및 부프레노르핀 시장 분석 : 투여 경로 시장별
  • 날트렉손
    • 시장 매출 추정과 예측(2018-2030년)
    • 경구 투여
    • 주사제 투여
    • 이식형 투여
  • 부프레노르핀
    • 시장 매출 추정과 예측(2018-2030년)
    • 경구 투여
    • 주사제 투여
    • 이식형 투여

제6장 날트렉손 및 부프레노르핀 시장 분석 : 용도별(2018-2030년)

  • 날트렉손 및 부프레노르핀 : 용도 변동 분석
  • 날트렉손 및 부프레노르핀 시장 분석 : 용도 시장별
  • 날트렉손
    • 시장 매출 추정과 예측(2018-2030년)
    • 오피오이드 사용 장애(OUD)
  • 부프레노르핀
    • 시장 매출 추정과 예측(2018-2030년)
    • 오피오이드 사용 장애(OUD)

제7장 날트렉손 및 부프레노르핀 시장 분석 : 유통 채널별(2018-2030년)

  • 날트렉손 및 부프레노르핀 : 유통 채널 변동 분석
  • 날트렉손 및 부프레노르핀 시장 분석 : 유통 채널 시장별
  • 원내 약국
    • 시장 매출 추정과 예측(2018-2030년)
  • 소매 약국
    • 시장 매출 추정과 예측(2018-2030년)
  • 기타
    • 시장 매출 추정과 예측(2018-2030년)

제8장 날트렉손 및 부프레노르핀 시장 : 제품별, 투여 경로별, 용도별, 유통 채널별 지역 추정·동향 분석

  • 날트렉손 및 부프레노르핀 시장 : 지역별 전망
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제9장 경쟁 상황

  • 시장 진출 기업 분류
  • 주요 기업 개요
    • Indivior PLC
    • Collegium Pharmaceutical, Inc.(BioDelivery Sciences International, Inc.모회사)
    • Alkermes plc
    • Orexo AB
    • Titan Pharmaceuticals, Inc.
    • Omeros Corporation
    • F. Hoffmann-La Roche Ltd.
    • Camurus
    • Sun Pharmaceutical Industries Ltd
    • Braeburn, Inc.
ksm 24.09.02

Naltrexone And Buprenorphine Market Growth & Trends:

The global naltrexone and buprenorphine market size is expected to reach USD 8.42 billion by 2030, growing at a CAGR of 12.41% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing growth primarily due to the rising incidence of substance use disorders, increasing government efforts to address the crisis, and growing awareness of treatments for opioid use disorder. These factors are anticipated to substantially boost industry expansion during the forecast period, fostering advancements and improving accessibility to addiction care solutions.

The World Drug Report 2023 highlights global trends in drug use disorders, emphasizing opioids as the primary cause of death from overdose and significant contributors to years lost due to disability and premature death. Opioid Use Disorder (OUD) affects millions worldwide, with disparities in treatment access exacerbated by the COVID-19 pandemic. Regional variations in primary drugs of abuse include opioids in Europe and Asia, cocaine in Latin America, and methamphetamine in East & Southeast Asia. Stigma and discrimination hinder treatment efforts, with less than 20% of those needing help receiving it. The report calls for international cooperation to address these complex health and societal challenges.

Furthermore, increasing government initiatives to combat the OUD crisis through multifaceted approaches are growing. In February 2024, with the approval of the SAMHSA, USD 46.6 million in supplemental Community Mental Health Services Block Grant and Substance Use Prevention, Treatment, and Recovery Services Block Grant funds have been allocated to mental health and substance use services. In addition, USD 67.5 million from U.S. Department of Treasury funds has been directed to support these efforts in Wisconsin.

Moreover, industry players are driving growth in the market through strategic initiatives, such as enhanced distribution networks, strategic partnerships with healthcare providers, and increased research and development investments. For instance, in July 2023, Titan Pharmaceuticals, Inc. and Fedson, Inc. signed an Asset Purchase Agreement, under which Titan would sell part of ProNeura assets, such as its portfolio of medications for drug addiction and other early development initiatives built on the ProNeura drug delivery technology. The company's addiction portfolio comprised implant programs for Nalmefene and Probuphine. In addition, in September 2023, Camurus AB introduced Brixadi, a weekly and monthly medication containing Brixadi, indicated to treat moderate-to-severe OUD. These efforts aim to expand treatment accessibility and efficacy, propelling advancement significantly.

Naltrexone And Buprenorphine Market Report Highlights:

  • North America accounted for the largest revenue share of 39.39% in 2023, driven by robust healthcare infrastructure, high prevalence of substance use disorder, and proactive government initiatives supporting addiction treatment.
  • Based on product, the buprenorphine segment dominated the market with a share of 70.02% in 2023 and is anticipated to witness the fastest growth at a CAGR over the forecast period. The segment growth can be attributed to the various strategies adopted by key players such as product launches, collaboration, M&A, regulatory approvals, clinical trials proving efficacy, & other factors that enhance treatment initiation rates.
  • Based on route of administration, the oral administration segment held the majority share of 55.87% in 2023. However, in buprenorphine segment, the injectable administration segment held the majority share of 65.04% in 2023.
  • Based on application, the OUD segment dominated the market with a share of 69.03% in 2023. Naltrexone is widely recognized for their efficacy in managing OUD, leading to its extensive adoption in treatment programs.
  • Based on distribution channel, the hospital pharmacies segment dominated the global market with a share of 48.26% in 2023. Growth can be attributed to their key role in administering parenteral OUD treatments, such as buprenorphine, ensuring physician-supervised care, and facilitating access to essential medications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Route of Administration Segment Snapshot
  • 2.3. Application and Distribution Channel Segment Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, and Scope

  • 3.1. Naltrexone and Buprenorphine Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing prevalence of substance use disorders
      • 3.2.1.2. Growing government initiatives to combat the crisis
      • 3.2.1.3. Increasing awareness of opioid use disorder treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Retention and adherence challenges
  • 3.3. Naltrexone and Buprenorphine Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
  • 3.5. Pricing Analysis
  • 3.6. Patient and Provider Considerations in Choosing Implantable Treatments
  • 3.7. Target Population Analysis
  • 3.8. Total Addressable Market (TAM) Analysis for Naltrexone & Buprenorphine Subcutaneous Absorbable Implants

Chapter 4. Naltrexone and Buprenorphine Market Analysis, by Product, 2018 - 2030 (USD Million)

  • 4.1. Naltrexone and Buprenorphine: Product Movement Analysis
  • 4.2. Naltrexone and Buprenorphine Market Analysis, by Product Market (USD Million)
  • 4.3. Naltrexone
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Buprenorphine
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. BELBUCA
      • 4.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Sublocade
      • 4.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Suboxone
      • 4.4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Zubsolv
      • 4.4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Naltrexone and Buprenorphine Market Analysis, by Route of Administration, 2018 - 2030 (USD Million)

  • 5.1. Naltrexone and Buprenorphine: Route of Administration Movement Analysis
  • 5.2. Naltrexone and Buprenorphine Market Analysis, by Route of Administration Market (USD Million)
  • 5.3. Naltrexone
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Oral Administration
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Injectable Administration
      • 5.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Implantable Administration
      • 5.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Buprenorphine
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Oral Administration
      • 5.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Injectable Administration
      • 5.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Implantable Administration
      • 5.4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Naltrexone and Buprenorphine Market Analysis, by Application, 2018 - 2030 (USD Million)

  • 6.1. Naltrexone and Buprenorphine: Application Movement Analysis
  • 6.2. Naltrexone and Buprenorphine Market Analysis, by Application Market (USD Million)
  • 6.3. Naltrexone
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Opioid use disorder (OUD)
      • 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.2.2. Alcohol use disorder (AUD)
      • 6.3.2.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Buprenorphine
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Opioid use disorder (OUD)
      • 6.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Naltrexone and Buprenorphine Market Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 7.1. Naltrexone and Buprenorphine: Distribution Channel Movement Analysis
  • 7.2. Naltrexone and Buprenorphine Market Analysis, by Distribution Channel Market (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates and Trend Analysis by Product, by Route of Administration, by Application, by Distribution Channel

  • 8.1. Naltrexone and Buprenorphine Market: Regional Outlook
  • 8.2. North America
    • 8.2.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.2.3. Competitive/Market Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement scenario
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Canada Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.3.3. Competitive/Market Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.4.3. Competitive/Market Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
  • 8.3. Europe
    • 8.3.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. UK Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.2.3. Competitive/Market Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.3.3. Competitive/Market Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.4.3. Competitive/Market Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
    • 8.3.5. Spain
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.5.3. Competitive/Market Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.6.3. Competitive/Market Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.7.3. Competitive/Market Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.8.3. Competitive/Market Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
    • 8.3.9. 6.3.9 Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.9.3. Competitive/Market Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Rest of Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.2.3. Competitive/Market Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.3.3. Competitive/Market Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.4.3. Competitive/Market Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.5.3. Competitive/Market Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.6.3. Competitive/Market Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.7.3. Competitive/Market Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Rest of Asia Pacific Naltrexone and Buprenorphine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Brazil Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.5.2.3. Competitive/Market Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Argentina Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.5.3.3. Competitive/Market Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Rest of Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. 6.6 MEA
    • 8.6.1. MEA Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.2.3. Competitive/Market Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.3.3. Competitive/Market Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.4.3. Competitive/Market Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.5.3. Competitive/Market Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
    • 8.6.6. Rest of MEA Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Key Company Profiles
    • 9.2.1. Indivior PLC
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Product benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. Collegium Pharmaceutical, Inc. (Parent company of BioDelivery Sciences International, Inc.)
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Product benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. Alkermes plc
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Product benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. Orexo AB
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Titan Pharmaceuticals, Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Omeros Corporation
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. F. Hoffmann-La Roche Ltd.
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Camurus
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Sun Pharmaceutical Industries Ltd
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Braeburn, Inc.
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제